BioSpace News Archive

InMed Pharmaceuticals Inc. (“InMed” or “the Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing cannabinoid-based medications targeting diseases with high unmet medical needs, today announced that Eric A. Adams, President & CEO will be presenting at the Biotech Showcase conference to be held at the Hilton San Francisco Union Square in San Francisco, California

Next Step in Alcami’s Strategic Plan to Focus its Platform on High-Growth Market Segments

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will webcast a live presentation at the 38th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco

Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the first pancreatic cancer patient has been dosed in Part 2 of the TYME-88-Panc pivotal trial designed to support approval of SM-88 (racemetyrosine) for the third-line treatment of patients with metastatic pancreatic cancer.

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Mark Pruzanski, M.D., President and Chief Executive Officer of Intercept, will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 15, 2020 at 10:00 a.m. Pacific Time.

Galen Partners announced the acquisition of Evolve Treatment Centers. Headquartered in Los Angeles, CA, Evolve is a leading adolescent behavioral health services provider, specializing in mental health, trauma, and substance abuse for adolescents in need.

Oryzon Genomics, S.A. announces that its management will present recent progress of vafidemstat in central nervous system indications at the 3rd Neuroscience Innovation Forum in San Francisco on January 12.

Rubius Therapeutics, Inc. announced the appointment of Laurence Turka, M.D., as its first chief scientific officer, effective January 21, 2020.

BioCardia®, Inc. announced the issuance of three new patents for the company’s technologies in the U.S., China and Japan.

CALQUENCE® (acalabrutinib) is now available for adult patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia